Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects
Phase 2
Recruiting
- Conditions
- NeuroblastomaNeuroectodermal TumorsNeoplasms
- Interventions
- Drug: 131I-MIBG
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Jubilant DraxImage Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT03561259
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸UCSF Pediatric Hematology/Oncology, San Francisco, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Expanded Access Protocol Using 131I-MIBG
- Conditions
- NeuroblastomaParagangliomaPheochromocytoma
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Jubilant DraxImage Inc.
- Registration Number
- NCT01590680
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Children's Healthcare of Atlanta, Atlanta, Georgia, United States
News
No news found